Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fujimoto Pharmaceutical Co.

Latest From Fujimoto Pharmaceutical Co.

SymBio shifts bendamustine's multiple myeloma focus to second-line use

SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.

Cancer Japan

Torisel among new approval recommendations in Japan

Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC).

Cardiovascular Cancer

Japan listing includes thalidomide for myeloma

Japan's Central Social Insurance Medical Council (Chuikyo) has granted reimbursement prices to a group of drugs including Fujimoto Pharmaceutical's thalidomide product Thaled for the orphan indication of refractory multiple myeloma.

Cardiovascular Cancer

Thalidomide gets a second chance in Japan

An advisory committee to Japan's ministry of health, labour and welfarehas recommended the approval of thalidomide for the treatment of refractory multiple myeloma, providing a new opportunity to a product banned in the country in 1962.

Cancer Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Fujimoto Pharmaceutical Co.
  • Senior Management
  • Kunisuke Fujimoto, Pres. & CEO
    Mitsuko Fujimoto, VP, CFO
    Yoshiro Inaba, Managing Dir.
  • Contact Info
  • Fujimoto Pharmaceutical Co.
    Phone: (81) 723 23 5151
    1-3-40 Nishi Otsuka 1-Chome
    Matsubara Shi, 580
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register